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Development of effective vaccines against emerging
infectious diseases (EID) can take as much or more than a
decade to progress from pathogen isolation/identiﬁcation to
clinical approval. As a result, conventional approaches fail to
produce ﬁeld-ready vaccines before the EID has spread
extensively. Lassa is a prototypical emerging infectious
disease endemic to West Africa for which no successful
vaccine is available. We established the VaxCelerate
Consortium to address the need for more rapid vaccine
development by creating a platform capable of generating
and pre-clinically testing a new vaccine against speciﬁc
pathogen targets in less than 120 d. A self-assembling
vaccine is at the core of the approach. It consists of a fusion
protein composed of the immunostimulatory Mycobacterium
tuberculosis heat shock protein 70 (MtbHSP70) and the biotin
binding protein, avidin. Mixing the resulting protein (MAV)
with biotinylated pathogen-speciﬁc immunogenic peptides
yields a self-assembled vaccine (SAV). To meet the time
constraint imposed on this project, we used a distributed R&D
model involving experts in the ﬁelds of protein engineering
and production, bioinformatics, peptide synthesis/design and
GMP/GLP manufacturing and testing standards. SAV
immunogenicity was ﬁrst tested using H1N1 inﬂuenza
speciﬁc peptides and the entire VaxCelerate process was then
tested in a mock live-ﬁre exercise targeting Lassa fever virus.
We demonstrated that the Lassa fever vaccine induced
signiﬁcantly increased class II peptide speciﬁc interferon-g
CD4C T cell responses in HLA-DR3 transgenic mice compared
to peptide or MAV alone controls. We thereby demonstrated
that our SAV in combination with a distributed development
model may facilitate accelerated regulatory review by using
an identical design for each vaccine and by applying safety
and efﬁcacy assessment tools that are more relevant to
human vaccine responses than current animal models.
Introduction
Following its failure to effectively deploy vaccines in response
to the H1N1 influenza pandemic in 2009 the US federal govern-
ment increased its capacity to respond to pandemic influenza
threats.1 The predominant focus of current emerging infectious
diseases (EIDs) countermeasure development has been on
broadly applicable post-exposure therapeutics rather than vac-
cines.2 Therapeutic countermeasures have their limitations
including the fact that the diversity of EID pathogens suggests
that targeted approaches will still be required to provide sufficient
protection and/or treatment either before or after exposure.3
Broad countermeasures such as post-exposure monoclonal anti-
bodies also face significant regulatory issues for eventual use in
humans.4 In contrast, prophylactic vaccines are generally thought
to be the most effective means of protecting against disease and
transmission and thus represent the most promising approach for
preparedness.2
The diversity of pathogen targets (viral, bacterial, fungal, para-
sitic) and host immune responses often results in significantly
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different vaccine strategies, which in turn produce vaccines that
are quite structurally diverse. The resulting proliferation of vac-
cine structures complicates vaccine formulation and manufactur-
ing requirements each new candidate adding raising new
regulatory questions. Second, the potential for an EID’s abrupt
appearance and rapid spread requires vaccine development from
pathogen identification to final product in a matter of months.
In addition, the scale of deployment for such a vaccine is likely to
be significant—possibly in the millions of doses required to pro-
vide broad protective coverage.
With these considerations in mind, we established the Vax-
Celerate Consortium in 2011 to demonstrate that rapid, scalable
vaccine generation against unknown EIDs was technically possi-
ble.5 VaxCelerate is based on a genome-to-vaccine approach and
assumes as little as one pathogen genome would be available at
the start of an outbreak. While a separate vaccine would be pro-
duced for every pathogen target, every vaccine would be made
essentially the same way to reduce regulatory review using a
broadly applicable vaccine platform. Excluding adjuvants would
reduce regulatory and manufacturing complexities. Finally, the
platform would offer a credible way to make rapid production of
millions of doses of the specific vaccine possible within a matter
of months.
The two key technologies leveraged to simultaneously
address these requirements are in silico antigen design, and a
self-assembling vaccine construct. An integrated set of
computational tools is used to mine an infectious agent’s
genomes to identify candidate vaccine antigens with key
properties such as predicted secretion and virulence. Validated
immunoinformatics tools are then used to map protein
sequences for HLA class I and II epitopes that are predicted
to be immunogenic and broadly reactive.
The second technology, the self-assembling vaccine (SAV),
enables assembly of multiple epitope peptides into a broadly
applicable vaccine platform. The SAV consists of 2 portions: a
fusion protein of M. tuberculosis heat shock protein 70
(MtbHSP70) and avidin (MAV) and a set of biotinylated pepti-
des containing the class I and class II epitopes identified by the in
silico screening method.
The recombinant MTBHsp70 protein’s immunostimula-
tory functions include activation and maturation of mono-
cytes and dendritic cells (DCs), enhancing antigen processing
and presentation.7 Furthermore, the mycobacterial protein
stimulates production of CC-chemokines that attract macro-
phages, and effector T and B cells,6,7 induction of the cyto-
toxic activity of natural killer cells,8 and improved cross-
priming of T cells which is dependent on DCs.9 These func-
tions and biology of HSP70 may play an important role in
the function of SAV.
Here, we report efforts to generate a vaccine against Lassa
fever and complete a key immunogenicity study of the vaccine in
120 d. As part of this project, early-phase good manufacturing
practices were implemented for component supply and construc-
tion of the final vaccine and the mouse study of the vaccine were
completed under good laboratory practices to increase the reli-
ability and reproducibility of the data.
Lassa fever virus (LV) is an arenavirus infecting between
300,000 and 500,000 individuals per year in West Africa with a
case fatality rate of 1–2% and a reported case-fatality rate climb-
ing to 15% in hospitalized patients.10 Although Lassa fever has
been reported in other countries (Germany, Netherlands, United
Kingdom and the United States) it is likely a product of interna-
tional travels. The large morbidity/mortality toll, the possibility
that LV could be developed as a biological warfare agent, the lack
of timely diagnosis and limited treatment options further stress
the need for the development of an effective vaccine. In spite of
significant research efforts no viable vaccine clinical trial candi-
date is on the horizon.11
The presence of LV specific IgM and IgG does not seem to
affect survival outcomes and sera from convalescing patients fail
to protect against infection.10 In non-human primates (NHP),
high titers of non-neutralizing antibodies correlate with survival
providing strong evidence that cell mediated immunity is at the
core of the protective immune response.11,12 In NHP studies,
rapid and strong cytotoxic lymphocyte (CTL) responses posi-
tively impact survival. Protective immunity to Lassa is largely a
function of a T cell-mediated immune response to the virus13-16
this is one of the rationales for testing the VaxCelerate platform
with this virus.
The virus is composed of 2 ambisense RNA strands, L (7-kb)
and S (3-kb). Its RNA encodes 5 proteins, L protein (RNA poly-
merase), NP (nucleocapsid), Z protein (RING, matrix), glyco-
protein 1 (GP1) and glycoprotein 2 (GP2).17,18 GP1 and GP2
are the products of the cleavage of the precursor protein GPC.
Candidates for antigen targeting within the Lassa virus include
the G protein (with the precursor molecule glycoprotein C,
GPC, post-translationally cleaved into a stable signal peptide,
SSP, and 2 subunits glycoproteins GP1 and GP2), the nucleo-
protein (NP), the L protein and the Z protein. In a prospective
study, a number of cross-reactive epitopes from various patho-
genic arenaviruses were identified and shown to offer the poten-
tial for wide ranging immunity.19 Recently, a DNA vaccine
encoding the subunits GP1 and GP2 resulted in protection of
vaccinated animals in a guinea pig challenge study,20 suggesting
that a subunit vaccine should confer protective immunity. We
designed a subunit vaccine consisting of MtbHSP70-avidin cou-
pled to immunogenic peptides from Lassa GP1 and GP2 pro-
teins. To meet the constrained time requirement for this project
we used a distributed R&D model that has been previously
described.5 The network included experts in the fields of protein
engineering and expression and purification (Pfenex), bioinfor-
matics (EpiVax), peptide manufacture/design (21st Century Bio-
chemicals) and Good Manufacturing Practice (GMP)/Good
Laboratory Practice (GLP) and testing standards (MPI Research).
The resultant vaccine candidate was tested in a transgenic HLA-
DR3 mouse model to assess CD4C T helper responses to the
human HLA-specific peptides.
We present the successful implementation of a model vaccine
development using a distributed R&D approach. First, we dem-
onstrated in a pilot study that the self-assembled vaccine could
trigger an immune response comparable to a known peptide
based vaccine in the HLA-DR3 mouse model. Second, the
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self-assembled Lassa fever virus specific vaccine triggered a signifi-
cant Th1 response in splenocytes from immunized animals when
challenged with a pool of HLA class II specific peptides as com-
pared to the peptides alone.
Results
Characterization of recombinant MtbHSP70-avidin
expressed in Pseudomonas
fluorescens
The MAV protein was produced
by Pfenex (San Diego, CA) and char-
acterized for purity, ATPase activity
and ability to bind biotin. Figure 1
depicts the fusion construct between
MtbHSP70 and avidin. As shown in
Figures 2 (A, B), the protein was
greater than 90% pure by polyacryl-
amide gel electrophoresis (PAGE)
and by capillary gel electrophoresis
(CGE). To evaluate proper protein
folding of the MtbHSP70 portion,
we assessed the ability of the MAV
protein to hydrolyze ATP. As shown
in Figure 2C, the ATPase activity
was linear over a wide concentration
range. Finally, we assessed the ability
of the avidin component to bind bio-
tin using a biotinylated HRP assay.
The protein was incubated with
excess biotinylated HRP for 20
minutes. Unbound biotinylated
HRP was removed with streptavidin
magnetic beads. Biotinylated HRP
bound to MtbHSP70-avidin remains
in solution and therefore can react
with tetramethylbenzidine. As shown
in Table 1A, the avidin portion of
the fusion protein was functional as
evidenced by the amount of HRP
activity remaining in solution when
MtbHSP70avidin was present.
Peptide design optimization
using an ovalbumin immunization
model
In order to understand how the
design of biotinylated peptides
impacts antigen processing and cell
mediated immunity we used the oval-
bumin/C57BL/6 model to take
advantage of well-characterized class I
and class II epitopes.21,22 We tested
the effects of peptide designs incorpo-
rating furin cleavage sequences
(RVKR) and a polyethylene glycol spacer on CD4C and CD8C T
cell to SAV-OVA vaccine. Mice were immunized with self-assem-
bled ovalbumin (OVA) peptides with and without furin cleavage
sites and with and without PEG (Fig. 1B and Table 2A). All pepti-
des successfully assembled at>95 % according to the biotinylated
HRP assay (Table 1B). Immunization consisted of an intradermal
prime injection followed by 2 intradermal boosts. We assessed
cell-mediated immune responses in isolated lymph node cells and
splenocytes. After stimulating cells with the class I epitope,
Figure 1. Depiction of self-assembled vaccines structures. (A) Structure of MtbHSP70-avidin (MAV) and
biotinylated antigens. (B) Structures of OVA peptides for SAV-OVA studies described in Table 2A. (C) and
(D) Structures of short (C) and long (D) Flu peptides described in Table 2B for SAV1 and SAV2 used in Flu
study.
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SIINFEKL, we analyzed the immune response by flow cytometry
looking at CD3C CD8C cells producing interferon-g. As shown
in Figure 2 E, we observed cell mediated immune responses in
SIINFEKL-stimulated lymph node cells in
the group immunized with self-assembled
peptides containing biotin, PEG, a leader
segment, and RVKR (peptide 3 Table 2).
Mice immunized with saline, MAV alone or
the control LKEFNIIS self-assembled vac-
cine did not respond to SIINFEKL-
stimulation.
HLA-DR3 mice respond to
immunization with a self-assembled
vaccine
We next tested whether the SAV plat-
form could enhance vaccine responses in
HLA-DR3 mice, the strain to be used in the
Lassa vaccine study. A pilot experiment using HLA class II pepti-
des against H1N1 influenza that induced significant class II T
cell responses in a DR3 mouse model was performed.23 The pilot
Figure 2. Characterization of Pfenex’ MtbHSP70-
avidin (MAV). (A) 500 nanograms of MAV were
electrophoresed on a 4–12% Bis-Tris NuPAGE
gel run in MOPS buffer at constant 200 V for
1 hr. (B) Reproduction of the capillary gel elec-
trophoresis (CGE) proﬁle provided by Pfenex.
150 nl of puriﬁed MAV (976.2 ng/nl) were
injected into the microﬂuidic channel of the Lab-
Chip GX/II using electrokinetic injection. Apply-
ing a voltage across the channel effected
protein separation. Protein bands were detected
via laser induced ﬂuorescence. Arrows indicate
the migration position of MtbHSP70-avidin.
(C) MtbHSP70-avidin ATPase activity assessment.
A series of MtbHSP70-avidin concentrations (25
– 500 ng) were incubated as described in mate-
rials and methods. (D, E, F and G) Flow cytomet-
ric analysis of splenocytes and lymph node cells
from ovalbumin immunized mice as described
in Materials and Methods. Splenocytes (D, F)
and lymph node cells (E, G) were prepared as
described in Materials and Methods and stimu-
lated with medium alone, SIINFEKL (D, E; 10 mg/
ml) or ISQAVHAAHAEINEAGR (F, G; 10 mg/ml)
for 24 hours at 37C. The percent of
CD3CCD8CIFN-gC and CD3CCD4CIFN-gC cells
above medium alone was determined and plot-
ted as percent above control. (H) Gel-shift assay
of SAV1 and SAV2. 400 to 800 ng of protein
were denatured and subjected to electrophore-
sis on a Novex 4–12% Bis-Tris NuPAGE gel run
in MOPS buffer at constant 200 V for 5 hr.
Arrows indicate MAV, SAV1 and SAV2. (I) SAV1
and SAV2 ATPase activity. Three different con-
centrations of MAV, SAV1 and SAV2 were
assayed for their ability to hydrolyze ATP as
described in Materials and Methods. Abbrevia-
tions: MAV - Mycobacterium tuberculosis heat
shock protein 70 fused to avidin; OVA - ovalbu-
min; PEG - polyethylene glycol; SAV1 - MAV
assembled with ﬂu speciﬁc peptides 1–4
(Table 2B); SAV2 - MAV assembled with ﬂu spe-
ciﬁc peptides 5 and 6 (Table 2B).
www.landesbioscience.com 3025Human Vaccines & Immunotherapeutics
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study compared responses between a DNA/peptide vaccine previ-
ously used to deliver the H1N1 epitopes (FluVax) and an influ-
enza SAV using the same peptides.24 Sequences of the peptides
used in both types of vaccines are detailed in Figure 1C and 1D
and Table 2B.
In light of reports that high doses of MtbHSP70 could be tol-
erogenic, we designed a way to reduce the amount of the core
protein in SAV by increasing the immunogenic peptide amount
using concatenated epitopes.25,26 In this study we compared T
cell mediated peptide specific immune responses to SAV assem-
bled with both shorter (40–45 amino acids) peptides and (60–65
amino acids) concatenated peptides. The vaccine with shorter
peptides (SAV1) was comprised of an equimolar mixture of 4 dif-
ferent protein-peptide constructs, with each construct containing
one of the 4 class II epitopes. SAV2 consisted of an equimolar
mixture of 2 protein-peptide constructs, with each construct con-
taining 2 different concatenated class II epitopes. The class II
peptides in SAV2 were separated by a furin cleavage site
(Table 2B). All the biotinylated peptides self-assembled with
MtbHSP70-avidin and we characterized the product of self-
assembly by gel shift assay and ATPase activity measurements
(Figs. 2H, I). We showed that biotinylated peptides self-assembly
were essentially complete and that the ATPase activity was main-
tained in the process.
The immunization schedule previously established for FluVax
was replicated in this study (see Method section).23 SAV immu-
nization was synchronized with this schedule by starting SAV
immunizations 14 d after the initial FluVax DNA electropora-
tion prime (Table 3A). Mice were bled on days -3, 14, 28 and
35. We assessed the effectiveness of each vaccine at stimulating
immune memory by isolating lymph node lymphocytes and sple-
nocytes from each of the 4 groups, stimulating these with the
individual influenza immunizing peptides and then analyzing
resultant CD3CCD4C interferon-g expression by flow cytome-
try. Results of peptide stimulation are shown in Figure 3. Spleno-
cytes from Fluvax-immunized mice responded robustly when
stimulated with individual influenza peptides, while splenocytes
from SAV2 immunized mice showed modest responses to 3 of
the influenza peptides. The robust splenocytes response from
FluVax-immunized mice was appropriate to the intramuscular/
intraperitoneal mode of administration and chemical adjuvanting
of the FluVax peptides with 6MDP, CLO97, and CpG1826.23
Lymphocytes from FluVax-, SAV1- and SAV2-immunized mice
all showed measurable responses to many of the individual influ-
enza peptides compared to medium alone. Surprisingly, lymph
node lymphocytes from MAV-treated mice also responded when
stimulated with influenza specific peptides. SAV2-stimulated
lymphocytes also showed robust CD3CCD4CIL-4C cell
responses to peptide stimulation, which was not seen in mice
immunized with FluVax, MAV or SAV1 (Fig. 3B). Finally, anal-
ysis of sera from vaccinated and control animals revealed that
only mice receiving FluVax had significant antibody titers against
the peptide components of the vaccine. In contrast, mice receiv-
ing MtbHSP70-avidin or the self-assembled vaccine had measur-
able antibody titers against MtbHSP70 (Table 4A).
Design of immunogenic Lassa fever virus peptides
The key considerations used in constructing targeting peptides
for the test vaccine were as follows: 1) limit class I and class II
peptides to the Lassa glycoproteins, 2) ensure peptides include
class I and class II targets from both GP1 and GP2, 3) ensure
coverage of all HLA super types with both with both the class I
and class II peptides, 4) maximize the number of peptides deliv-
ered per unit of MtbHSP70-avidin, 5) optimize the solubility of
the peptide strings, 6) combine class I and class II peptides in
each peptide string, 7) include cleavage sequences to direct anti-
gen processing and cross presentation, and 8) minimize potential
junctional immunogenicity created by juxtaposition of epitopes
and flanking sequences that could result in non-specific immuno-
genic responses.
The resultant peptide set generated using these criteria is shown
in Tables 2C and D. The sequences of the final peptide constructs
used in the SAVLassa (SAVL), including the location of the anti-
gen processing cleavage sequences, are shown in Figure 4. Assem-
bly of each peptide to MtbHSP70-avidin was monitored and was
reported to be >95 % complete. The ATPase activity of the self-
assembled vaccine is shown in Figure 5 A. We observed a 22 to
50% reduction in ATPase activity when MTBHsp70-avidin was
assembled with the SAV1 peptide (MAVf) or with the long Lassa
fever virus specific peptides (Fig. 5A). We surmise that this is
related to the length and structure of the bound peptide(s). This is
in contrast to the SAV2 vaccine, which was assembled with
concatenated Flu peptides (Fig. 2G).
Testing the efficacy of a self-assembled vaccine for
Lassa fever
The fully assembled Lassa SAV (SAVL) was formulated for
injection and then tested for its ability to induce a CD4 T helper
cell response in HLA-DR3 mice. Prior to immunization, the
flow cytometry intracellular assays were validated for the detec-
tion of interferon-g in CD3CCD4C lymphocytes from spleens
and lymph node cells. The validation included intra-assay
Table 1. Biotin binding assay of MAV and SAV
A. MtbHSP70avidin biotin binding assessment*
Condition OD 450–650 nm
Biotin-HRP 0.33 C/¡ 0.12
Biotin-HRP C MtbHSP70avidin 2.35 C/¡ 0.24
B. Percent self-assembly of biotinylated peptides
Peptide # OD 450 – background % completion
1 0.01 C/¡ 0.014 99.0
3 0.012 C/¡ 0.003 98.8
4 0.015 C/¡ 0.001 98.5
5 0.005 C/¡ 0.007 99.9
*Biotin-HRP was incubated with or without MtbHSP70-avidin. Unbound bio-
tin-HRP was removed by addition of magnetic Streptavidin beads. An ali-
quot of the resulting supernatant was mixed with Tetramethylbenzidine
and incubated in the dark for 5 minutes. The reaction was stopped with 2N
H2SO4 and reaction read at 450 nm after subtracting background at
650 nm. All reactions were performed in duplicates
3026 Volume 10 Issue 10Human Vaccines & Immunotherapeutics
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precision, inter-analyst precision, and stability testing post-fixa-
tion and sample analysis with and without PMA/Ionomycin.
Other endpoints such as the presence of IL-4, Granzyme B and
IL-17 were optimized but were not part of the cGLP validation
studies.
Immunization was performed as described in Table 3B. Iso-
lated lymph node cells and splenocytes were stimulated with a
pool of class II peptides to assess immune memory. Figure 5B
illustrates the flow cytometric analysis and gating strategy used
for CD3CCD4CIFN-gC splenocytes. For each mouse, we calcu-
lated the resultant values from splenocytes or lymphocytes stimu-
lated with medium alone versus peptides. These were expressed
either as the number of net positive cells per 106 splenocytes or
lymph node cells, or the percentage of net positive cells of the
total CD4C T cell population. As shown in Figure 5C, spleno-
cytes from 10 of 11 SAVL immunized mice responded to the
pool of class II Lassa fever virus specific peptides. Similarly, sple-
nocytes from 7 of 8 mice immunized with peptides alone and
splenocytes from 11 of 12 mice immunized with MAVf
responded to the pool of class II peptides compared to mice
injected with PBS only.
The results of the study were positive with respect to the pri-
mary end point, showing that splenocytes from mice vaccinated
with SAVL generated a statistically significant increase in
CD3CCD4CIFN-gC T cells in response to stimulation with the
Lassa-specific class II peptides compared to splenocytes from
mice exposed to PBS alone (Fig. 5C; p D 0.0049; Kruskal-Wallis
with Dunn’s multiple comparisons test). The median values for
the SAVL vaccinated mice were 891 CD3CCD4CIFN-gC T cells
per 106 splenocytes (0.48% of the CD4C T cells). Splenocytes
from mice vaccinated with either peptide alone or with MAVf
also showed an increase in these values (median values of 508
Table 2. Epitopes and peptides sequences used for OVA, Flu and Lassa fever virus vaccines
A. Sequences of Ovalbumin speciﬁc peptides
Peptide# Sequence
1 Biotin-LEQLErvkrSIINFEKLrvkrISQAVHAAHAEINEAGR
2 PEG(4)-LEQLErvkrSIINFEKLrvkrISQAVHAAHAEINEAGR
3 Biotin-PEG(4)-LEQLErvkrSIINFEKLrvkrISQAVHAAHAEINEAGR
4 Biotin-PEG(4)-LEQLEvrvvSIINFEKLvrvvISQAVHAAHAEINEAGR
5 Biotin-PEG(4)-LEQLErvkrLKEIINSFrvkrISQAVHAAHAEINEAGR
B. Peptides used for the Flu study
Number Name Sequence
1 FLUVAX_2008-09_321 Biotin-PEG-rvkrCPKYVRSAKLRMVTGLRNIPS
2 FLUVAX_2011 HA2 Biotin-PEG-rvkrAEMLVLLENERTLDYYDS
3 FLUVAX_2011 HA6 Biotin-PEG-rvkrYEKVRSQLKNNAKEIGNGC
4 FLUVAX_2011 HA7 Biotin-PEG-rvkrGAVSFWMCSNGSLQFRI
5 1C2 Biotin-PEG-rvkrCPKYVRSAKLRMVTGLRNIPSrvkrAEMLVLLENERTLDYYDS
6 3C4 Biotin-PEG-rvkrYEKVRSQLKNNAKEIGNGCrvkrGAVSFWMCSNGSLQFRI
C. Lassa speciﬁc Class I peptides
Lassa Peptide Frame AA Frame A0101 A0201 A0301 A2402 B0702 B4403 Hits Sum of
Protein Length Start Sequence Stop Z-Score Z-Score Z-Score Z-Score Z-Score Z-Score Scores
GP 9 411 ITEMLQKEY 419 4.59 -0.84 1.65 0.01 -0.11 -0.01 2 6.24
GP 9 434 FVFSTSFYL 442 1.57 3.05 1.56 1.77 1.78 1.28 3 6.6
GP 9 312 MLRLFDFNK 320 -0.24 0.99 3.22 0.4 -0.03 -0.62 1 3.22
GP 9 139 TFHLSIPNF 147 0.16 -0.89 0.55 3.38 1.13 1.92 2 5.29
GP 9 237 SPIGYLGLL 245 -0.04 1.36 -0.35 1.29 3.16 1.59 1 3.16
GP 10 269 SEGKDTPGGY 278 1.84 -0.73 0.49 0.04 -0.12 3.51 2 5.35
GP 10 120 LSDAHKKNLY 129 4.19 -1.31 2.05 -0.19 -0.29 -0.12 2 6.24
GP 10 478 GLYKQPGVPV 487 0.17 2.23 0.51 -0.19 0.1 0.54 1 2.23
GP 9 344 LINDQLIMK 352 1.58 1.06 2.78 -0.39 -0.56 -0.97 1 2.78
GP 9 392 SYLNETHFS 400 0.28 0.13 -0.07 2.48 -0.54 -0.57 1 2.48
GP 9 452 IPTHRHIVG 460 -1.33 -1.28 -0.3 -0.33 2.44 -0.11 1 2.44
GP 9 328 AEAQMSIQL 336 0.18 0.53 -0.48 0.92 0.94 2.09 1 2.09
D. Lassa speciﬁc Class II peptides
Lassa Cluster Cluster
Hits
Cluster EpiBars?
Protein Address Sequence Score (#)
GP 159-177 GGKISVQYNLSHSYAGDAA 16 30.57 Yes (3)
GP 438-460 TSFYLISIFLHLVKIPTHRHIVG 18 30.24 Yes (2)
GP 330-348 AQMSIQLINKAVNALINDQ 16 30.18 Yes (1)
GP 127-151 NLYDHALMSIISTFHLSIPNFNQYE 17 27.81 Yes (2)
GP 238-255 PIGYLGLLSQRTRDIYIS 12 24.45 Yes (2)
GP 315-336 LFDFNKQAIQRLKAEAQMSIQL 15 24.34 Yes (2)
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and 482 CD3CCD4CIFN-gC T cells per 106 splenocytes respec-
tively), but these were not statistically significant when compared
to the PBS exposed group (median value of 64
CD3CCD4CIFN-gC T cells per 106 splenocytes).
Results from class II peptides stimulation of splenocytes and
lymph node cells were not statistically significant for CD3C
CD4CIL-4C, CD3CCD4CGzm-BC, and CD3CCD4CIL-17C
and all CD8C T cell responses. Since HLA-DR3 mice do not
express class I MHC no CD8C T cell responses were anticipated
or detected (data not shown).
Discussion
The VaxCelerate II project provides support for the concept
of a rapid and scalable vaccine platform for addressing abruptly
appearing EIDs of significant public health importance. We have
demonstrated that within 120 d a de novo vaccine could be gener-
ated based only on genomic information using scalable
manufacturing approaches and that the putative vaccine could
induce potent cell mediated immune responses in a human-rele-
vant mouse model (Fig. 6 for time line).
Production of the protein component of the vaccine was
optimized to consistently yield a highly purified functional pro-
tein as assessed by CGE, LDS-PAGE, ATPase activity and abil-
ity to bind biotinylated horse radish peroxidase (Figs. 2A, B, C
and Table 1A). It is interesting to note that, in contrast to a
self-assembled vaccine complex consisting of Streptavidin and
endogenous TLR4, we did not observe tetramer formation.27
The small shift observed upon assembly of peptides and
MtbHSP70-avidin made it difficult to rapidly assess completion
of the process. The use of biotinylated-HRP to assess the num-
ber of remaining biotin binding sites allowed us to test many
assembly conditions.
Table 3. Immunization schemes
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Figure 3. Flow cytometric analysis of splenocytes and lymphocytes from FluVax, SAV1 and SAV2 immunized mice. Splenocytes and lymphocytes were
prepared as described in Materials and Methods and stimulated with the indicated ﬂu peptides (10 mg/ml) or medium alone for 24 hours at 37C. Brefel-
din A was added 4 hours prior to harvest to inhibit protein transport. Cells were stained for CD3, CD4, CD8, IL-4 and interferon-g ﬁxed and analyzed on a
BD LSR FortessaTM. The percent of CD3CCD4CIFN-gC cells above medium alone was determined and plotted as percent above control. (A) Splenocytes
response, (B) lymph node cells response. The percent of CD3CCD4CIL-4C cells above medium alone was determined and plotted as percent above con-
trol for (C) splenocytes response, (D) lymph node cells response. Numbers in parenthesis indicate non-responders.
Table 4. Antibody responses against immunizing components of the vaccines*
A) FluVax Pilot experiment: Median (min; max)
Antigens\Immunization group MAV FluVax SAV1 SAV2
FluVax Peptides ND** 5756 ND ND
(0, 9243)
MtbHSP70 55735
(50205; 61815)
ND 6214
(60739; 63466)
6311
(55941; 6352)
B) Lassa Fever vaccine study: Median (min; max)
Antigens\Immunization group Saline Peptides MAVf SAVL
Lassa Speciﬁc peptides ND 1671*** ND 1753***
MtbHSP70 ND ND 59622
(54908; 66679)
59559
(27842; 62856)
*Endpoint titers using the method of Frey, A, Di Canzio, J., & Zurakowski, D. (1998). Titers determine as highest sera dilutions crossing the 95% conﬁdence
interval cutoff curve.
**ND; none determine. Sera dilutions at 1:100 yielded results below the 95% conﬁdence interval curve.
***Endpoint titer for pooled sera against peptide S6 (Fig. 4B). No titers were observed against the other peptides.
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We used the ovalbumin immunization model to assess the
optimal peptide assembly that would yield the optimal immune
response.22,28 Prior work with fusions of MtbHSP70 with large
segments of ovalbumin containing the class I specific SIINFEKL
peptide suggested that successful presentation relied on protein
processing.29,30 To improve class I processing of peptides in the
self-assembled vaccine, we drew on the work of Del Val et al.,31
showing that furin cleavage can preferentially drive class I MHC
processing.32-34 Lu et al., showed in a tumor model that the pres-
ence of a furin cleavage site (RVKR) and the combination of class
I and class II peptides improves CTL responses to a vaccine.35 To
facilitate furin cleavage we included a leader segment (LEQLE)
consisting of the 5 amino acid residues preceding ovalbumin’s
class I peptide SIINFEKL. The presence of PEG and a furin
cleavage site (RVKR) resulted in optimal presentation of SIIN-
FEKL and induction of CD8C T cell memory. While SAV cou-
pled to OVA peptide 3 (Table 2A) induced detectable class I
immune responses to SIINFEKL in the OVA model, class II T
cell responses were more modest compared to unvaccinated con-
trols (Figs. 2 F, G). The immune response was increased in
lymph node cells and was superior to whole protein
immunization adjuvanted with CFA/IFA. These results demon-
strated that the inclusion of a leader sequence, furin cleavage site
and PEG in the peptide component of SAV improved immuno-
genicity. The requirement for the furin cleavage site to augment
immunogenicity is consistent with prior studies showing that this
component improves peptide processing and cross-presenta-
tion.32-35
Before tackling the design of a Lassa fever virus specific vac-
cine we needed to confirm that the peptide framework would be
successful when applied to already optimized immunogenic pep-
tides. In collaboration with EpiVax we tested our approach using
the Flu peptides they optimized in their FluVax vaccine using the
transgenic HLA-DR3 mouse model.23 To maximize the antigen
dose per assembled complex, we tested the effect of concatenating
2 peptides separated by the furin cleavage site. As we had seen in
the ovalbumin model, the response was more pronounced in the
lymph node cells with our self-assembled vaccine although sple-
nocytes from mice immunized with SAV2 showed some positive
CD3C CD4C interferon-gC responses. Unexpectedly we
observed a very strong response to Flu peptides in lymph node
cells from mice immunized with MAV itself. We note that a
Figure 4. Structure and sequences of Lassa fever virus immunogenic peptides. (A) Basic framework for the synthesis of immunogenic concatenated class
I and class II peptides. (B) Biotinylated Lassa fever virus speciﬁc peptides.
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group of investigators from Germany have published a number
of studies showing that HSP70 has the capacity to bind human
HLA-DR molecules and induce proliferation of CD4C T
cells.36-38 This investigative team did not explore the implica-
tions of this activating HLA binding in the context of vaccines.
We believe that the potentiation of the CD4C vaccine responses
by the self-assembling protein in the context of this transgenic
HLA-DR3 mouse model may be reflective of this activating
binding capability of MtbHSP70 and may be one mechanism of
vaccine potentiation in humans. A Flu challenge study is planned
in order to assess the efficacy of MAV to induce a protective
immune response in transgenic mice. This immunostimulating
effect seen only in transgenic HLA-DR mice or in human sam-
ples also provides a concrete example of the limitation of the
wild-type mouse models for predicting human immune
responses and further emphasizes the value of developing more
human-like vaccine testing platforms. In order to minimize this
effect in the Lassa fever vaccine study we complexed the protein
with Flu peptide 4 (Table 2B).
We demonstrated that the self-assembled Lassa fever vaccine is
capable of inducing a significant increase in interferon-g positive
CD4C T cells in HLA transgenic DR3 mice compared to PBS
control. The vaccine group showed positive responses in spleno-
cytes but not in lymph node cells. The CD3CCD4CIFN-gC T
Figure 5. Characterization of the self-assembled Lassa fever virus vaccine (SAVL). A) ATPase activity of MAV, MAVf, and SAVL using 25, 50 and 100 ng. The
assay was carried out as described in Materials and Methods. (B) Flow cytometric analysis of splenocytes from mice immunized with SAVL. Splenocytes
from mice immunized with PBS, peptides, MAVf and SAVL were prepared as described and stimulated with medium alone or a pool of class II peptides
(10 mg/ml). Total incubation time was 24 hours at 37C. Brefeldin A was added 4 hours prior to harvest. (C) Comparison of splenocytes response to class
II Lassa fever virus speciﬁc peptides between different immunization groups.
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cell responses were comparable to those reported
in a number of other antiviral vaccine studies in
mice, non-human primates and humans, includ-
ing 2 vaccines that achieved market approval in
the US (Table 5). For example, when PBMCs
from yellow fever vaccinees were challenged in
vitro, 250 cells per millions had an interferon-
gC response in an ELISPOT assay (Table 5). In
Balb/c mice immunized against hepatitis C,
125–200 splenocytes per million showed a posi-
tive interferon-g response (Table 5). The
median number of CD4CIFN-gC splenocytes
response in our SAVL immunized mice was 891
cells per million splenocytes thus comparing
favorably with other vaccines.
Unlike our results with the class II influenza
peptides, the Lassa vaccine did not promote IL-
4 responses. These data support the view that
peptide composition plays a role in determining the type of
immune response induced by the vaccine platform. It is worth
noting that, while not reaching statistical significance, the peptide
vaccinated group showed an increase in response to stimulation
with class II peptides. The use of peptides (<55 amino acids) in
absence of adjuvant do not show such responses.23,39 It is possi-
ble that the use of immunogenic peptides greater than 60 amino
acids and including the use of furin cleavage sites have the ability
to increase immunity by themselves. Two prior studies demon-
strate the immunogenicity of peptides of this length without the
use of adjuvants.40,41 From this perspective; the peptide-only vac-
cination group should not be considered to be a negative control.
In addition, vaccination of mice with the MtbHSP70-avidin con-
struct (self-assembled to a non-Lassa peptide; MAVf) showed an
increase in response to stimulation with class II peptides. Again,
this increase was not statistically significant. This response was
similar to the potentiation of immune responses seen in the
HLA-DR3 transgenic mouse influenza vaccine study. These data
further support the work of Holzer et al., showing that HSP70
binding to HLA-DR molecules enhance class II-restricted pep-
tide presentation and CD4C T cell activation.36,37
Although our vaccine included 12 class I peptides, absence of
expression of human HLA class I in this mouse model precluded
us from investigating the effect of the vaccine on CD8C T cells.
Potential murine/human proteosomal processing differences are
likely shortfalls of testing this vaccine in double transgenic mice.
A more robust approach to quantitating the immunogenicity of
the designed peptides would be to assess the peptide-specific T
cell immune responses of convalescent individuals who survived
Lassa virus infection in endemic areas. A challenge study in non-
human primates using rhesus or cynomolgus monkeys would
also help assess the efficacy of our Lassa fever virus vaccine.15
In the process of designing the Lassa fever vaccine, we
reviewed subunit vaccine studies published over the last 15 y.
These studies have shown that use of NP, GPC or the 2 G pro-
teins or a combination of NP/GPC is protective in a variety of
animal models.10,14,15,42-56 Studies of convalescent sera from
patients with Lassa Fever or human HLA transgenic mice identi-
fied a number of epitope targets within the NP, GP1, GP2 and
GS proteins.11,12,16,19,57-63 Recent work in a guinea pig model
utilizing the GP1 and GP2 proteins in a DNA vaccine resulted
in adequate protection from challenge virus.13-16,20 Our review
of Lassa vaccine development efforts did not show that the Lassa
L protein has ever been used as part of the antigens in a subunit
vaccine, although the L protein was shown to be protective in
animal studies of other arenavirus like lymphocytic choriomenin-
gitis virus.17,18,64 In this setting, the L protein has been identified
in a guinea pig model as a virulence factor for the virus.19,65-67
The ML29 reassortment virus vaccine, comprising the L and Z
protein from Mopeia virus—an Old World arenavirus closely
related to Lassa—and the GPC and NP proteins from Lassa,
have also been effective in a number of vaccine stud-
ies.20,47,50,51,55 The L protein of Mopeia was chosen to serve as a
replication or translational attenuation factor in the vaccine.68,69
Table 5. Comparison of T cell immune responses observed in this study with other EID vaccines
Pathogen Vaccine Type Type of Subject Immuno-assay Response Citation
Lassa Protein-peptide complex Tg HLA-DR3 mice Flow cytometry 891 cells per 106 splenocytes; 0.59% of total CD4C T cells Current study
Dengue Attenuated virus Humans Flow cytometry Up to 0.16% of CD4C T cells See ref. 77
Hepatitis C Adjuvanted proteins BALB/c mice ELISpot 125–200 cells per 106 splenocytes See ref. 78
HIV BCG expression Gag Chacma baboons ELISpot 0.4% of CD4C T CELLS See ref. 79
Smallpox Attenuated live virus BALB B/c mice Flow cytometry 0.1–0.3% of CD4C T cells See ref. 80
Yellow fever Attenuated live virus Humans ELISpot Up to 250 cells per 106 PBMC See ref. 81
Figure 6. VaxCelerate time line.
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We therefore limited the peptide targets to class I and class II
peptides of the Lassa glycoproteins G1 and G2. This selection
also excluded targets against the Lassa nucleoprotein, which has
been targeted in some subunit vaccine candidates.14,21,42,44-48,50-
52,55,56
Although we detected an antibody response against the
MtbHSP70 component of the vaccine we failed to observe a
strong antibody response against the peptide component of the
vaccine. We attribute this lack of antibody response to the pep-
tide antigen to rapid uptake and processing. While the observed
strong Th1 response is promising it does not guarantee that this
vaccine is protective against Lassa fever virus. In order to further
qualify the chosen epitopes we plan to test PBMCs from recover-
ing Lassa fever virus patients. This would be followed by chal-
lenge study using a suitable animal model.
In conclusion, leveraging 2 key technologies, in silico antigen
design and a self-assembling vaccine construct, in combination
with a distributed R&D effort and an emphasis on testing in a
humanized transgenic animal model allowed us to accomplish
our stated goal of generating a vaccine candidate against Lassa
fever virus and performing a key immunogenicity study in 120 d.
The positive CD4C T cell responses induced by the SAV candi-
date further supports the feasibility of this approach to address
the multiple challenges posed by EIDs. Further testing of this
vaccine candidate is clearly required, including broader immuno-
genicity testing and pathogen challenge studies in non-human
primates. Further adaptations of this vaccine strategy may con-
tribute to improved defenses against bioterror agents, and could
eventually lead to the development of personalized ‘on demand’
vaccines for civilian populations.
Materials and Methods
Mice
For the Ovalbumin study we used 6–8 weeks old female
C57BL/6 mice from Jackson Laboratory. Female 6–8 weeks old
HLA-DR3 mice were obtained from Taconic under license to
EpiVax and were used in the Vax-Flu and Vax-Lassa studies.
Synthesis of MtbHSP70-avidin
Pfenex Inc. used its proprietary Pseudomonas fluorescens-based
platform technology to prepare 10 mg of MtbHSP70-avidin.
Briefly, cells expressing the target protein were lysed, and debris
was removed by centrifugation. The soluble fraction was chroma-
tographed over a His Trap FF column (GE Healthcare Life Sci-
ences) for initial purification. The flow through was reprocessed
over a His Trap FF column to improve the yield. The pooled
HisTrap elutions were further processed on a Sephacryl S-200
HR column (GE Healthcare Life Sciences) to remove co-purify-
ing contaminants. Finally, endotoxin levels were significantly
reduced by chromatography on EtoxiClearTM (ProMetic Bio-
sciences Ltd.), as measured by the Kinetic Chromogenic LAL
assay. The final endotoxin content was <50 EU/mg of protein.
Protein concentration was measured on an Eppendorf Biopho-
tometer by OD280. Correction for light scattering was performed
by subtracting the absorbance at 320 nm multiplied by 1.7. The
purity of the protein was assessed by capillary gel electrophoresis
with detection by laser-induced florescence on a LabchipGX/II
made by PerkinElmer (formerly Caliper Life Sciences, Inc.).
Finally, the intact mass analysis was performed by LC-MS using
an Agilent 1100 HPLC system and a Waters Q-TOF mass spec-
trometer with lock-mass correction. Deconvolution of the spectra
from the main peak was performed with Waters MaxEnt1
software.
Gel-shift assay
Assembly of MAV with the H1N1 peptides (Table 2B) and
Lassa fever virus peptides (Tables 2C and D; Fig. 4B) was
assessed using a gel-shift assay. 400 to 800 ng of MAV or SAV
were mixed with sample loading buffer, heated to 70C for 10
minutes prior to addition of dithiothreitol. The proteins were
subjected to electrophoresis on a 4–12% Bis-Tris NuPAGE gel
run in MOPS buffer at constant 200 V for 5 hrs. Ten microliters
of Novex Sharp pre-stained protein standards were added to
adjacent lanes. Protein bands were identified by staining with
RAPIDstain (Geno Technologies).
Immunogenic epitopes identification
Immunoinformatics
Epitope identification. The Lassa virus Josiah strain complete
sequence was downloaded from the National Center for Biotech-
nology Information (Accessions HQ688674 and HQ688672).70
Antigen sequences were downloaded in GenPept format, where
the accession number and corresponding amino acid sequence of
each of the 4 antigens were exported and then uploaded to an in-
house database. Per antigen, the amino acid sequence was parsed
into 9-mer peptides overlapping by 8 amino acids and analyzed
using EpiMatrix 1.2 to identify potential T cell epitopes.71 Pepti-
des scoring 1 .64 on the EpiMatrix “Z” scale (typically the top
5% of any given sample), are likely to be human leukocyte anti-
gen (HLA) ligands and are considered “hits." Class II epitopes
were identified for 8 archetypal alleles that cover >90 % of the
human population (DRB1*0101, DRB1*0301, DRB1*0401,
DRB1*0701, DRB1*0801, DRB1*1101, DRB1*1301 and
DRB1*1501).72 Class I epitopes were identified from among 9-
mer and 10-mer peptides for 6 “supertype” alleles: A*0101,
A*0201, A*0301, A*2402, B*0702, B*4401.73 Lassa antigens
were screened for regions of high Class II epitope density using
the ClustiMer algorithm for construction of broadly reactive vac-
cine immunogens 15–25 amino acids long.74 Class I sequences
do not cluster like Class II hits and did not undergo ClustiMer
analysis.
Homology analysis. The JanusMatrix algorithm was used to
analyze epitopes for human or commensal homologies.75 Janus-
Matrix screens HLA ligands for T cell receptor-facing sequence
patterns shared between pathogen and human or between patho-
gen and commensal, which may activate pre-existing cross-reac-
tive (inducible) regulatory T cells. Epitopes containing high
cross-reactive potential were discarded and Lassa virus-specific
epitopes were retained for vaccine formulations. Epitopes were
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also screened for homology to other Lassa strains and other are-
naviruses using JanusMatrix. Finally, epitopes were cross-refer-
enced against the Immune Epitope Database (IEDB) for Lassa
virus sequences that were reported to bind HLA and/or elicit a T
cell response.
Synthesis of immunogenic peptides
Five mg of each biotinylated immunogenic peptide selected as
defined above were prepared by Fmoc solid phase synthesis (21st
Century Biochemicals) and HPLC purified. Purity was assessed
by HPLC (peak area) and all peptides were >90% purity. The
mass and peptide sequence were confirmed by ESI-MS and tan-
dem MS, respectively, utilizing a QSTAR XL Pro Qo-TOF MS
(ABI-SCIEX). Three peptide designs were used in a process of
optimization for immunogenicity.
For the Ovalbumin study we tested the effect of Polyethylene-
glycol (PEG) and the furin cleavage substrate RVKR, on the
immunogenicity of the peptide. Therefore, peptides were
designed with and without PEG and with and without RVKR.
These are listed in Table 2. Flu peptides were composed of PEG
and a series of 4 epitopes similar to those present in FluVax.
These are listed in Table 2B. Finally; the Lassa fever virus specific
peptides are listed in Figure 4.
Vaccine self-assembly and assessment of reaction
Each peptide was assembled separately by simply mixing a 10-
fold molar excess of biotinylated peptide with MAV in PBS. The
reaction was allowed to proceed at room temperature for
12 hours by mixing end over end. Assembly was assessed as
described below and found to have reached greater than 95%
completion.
Assembly was assessed by measuring the amount of biotiny-
lated-HRP that could still bind to MAV. Briefly, the assay con-
sisted of taking a reaction aliquot (10 ml) and mixing it with
biotinylated HRP for 15 minutes in a final reaction volume of
100 ml. Excess biotinylated HRP was removed by addition of
10 ml streptavidin magnetic beads (Pierce) and incubation for 5
minutes. 50 ml of supernatants were transferred to an ELISA
plate followed by addition of 100 ml of TMB and incubation in
the dark for 10 minutes. The reaction was stopped by addition of
2N H2SO4 and read at 450 nm subtracting background at
650 nm. A low read out is taken as indicative that all avidin-
binding sites are occupied with peptides while a high read out
means that sites remain available. These readouts are always com-
pared to MtbHSP70-avidin unexposed to peptides.
ATPase assay
The ATPase assay was performed according to the man-
ufacturer’s recommendations (Innova Biosciences, ATPase Assay
Kit cat# 601–0121). Briefly, 25 to 500 ng of assembled or unas-
sembled MAV protein were incubated in 50 mM Tris pH 7.5
supplemented with 2.5 mM MgCl2 and 0.5 mM ATP. The
assay was carried out at 37C for 20 minutes and stopped by
addition of an acidic proprietary form of malachite green. Nega-
tive controls consisted of adding the protein mix after addition of
the stop solution. Color was allowed to develop for 30 minutes
at room temperature. ATP hydrolysis was assessed by determin-
ing the amount of Pi released based on the intensity of the OD at
650 nm.
Immunization protocols
Three immunization protocols were performed.
Ovalbumin immunization study
A total of 9 groups comprised of 6 animals per group were
used in this study. A series of peptides, described in Table 2A,
were tested in order to determine the optimum configuration for
self-assembly. Groups consisted of Saline, Ovalbumin (CFA/
IFA), peptide 2 (unbiotinylated) (CFA/IFA), MAV, MAV C
peptide 2 (unbiotinylated), MAV-Peptide 5 (no SIINFEKL),
MAV-Peptide 4 (no furin cleavage), MAV-Peptide 3 (furin cleav-
age), MAV-Peptide 1 (no PEG). All animals received a prime
intradermal injection on day 0, followed by intradermal boosts
on days 14 and 28. Mice received the equivalent of 12 mg of
MtbHSP70-avidin per injections. Mice were bled on day -3, 14,
28 and 35.
Influenza vaccine study
Twenty-four HLA-DR3 mice were divided into 4 groups (6
mice per group) immunized with FluVax2011, MtbHSP70-avi-
din, SAV1, SAV2. FluVax2011 immunization consisted of a
prime and boost intramuscular DNA electroporation on days 0
and 14 followed by subcutaneous peptide immunization on days
28 and 42. For peptides immunization a mixture of CLO97,
CpG182 and 6MDP adjuvants were used. MtbHSP70-avidin,
SAV1 and SAV2 were given intradermally (doses representing
12 mg of MtbHSP70) on days 0, 14 and 28. Bleeds were taken
on day -3, 14 and 38.
Lassa fever vaccine study
Four groups of mice, (12 mice per group), were immunized
intradermally with PBS, peptide alone, MAVf or SAVL. MAVf
consists of assembly of the fusion protein with Flu peptide num-
ber 4 described in Table 2B. The immunization schedule is
shown in Table 3A and consisted of a priming dose on day 0 fol-
lowed by boosting doses on days 14 and 28. Mice were bled on
days -3, 14, 28 and 35. Animals were euthanized on days 35 and
37. Each immunization consisted of 2 50 ml intradermal injec-
tions. Immunizations with peptide alone consisted of 2 mg doses
while MAVf and SAVL immunizations consisted of 12 mg of
MAV equivalent per dose.
Cell mediated immunity assay - flow cytometric analysis
Briefly, splenocytes were harvested from control and vacci-
nated mice. Red blood cells were lysed using M-Lyse (R&D
systems). The remaining lymphocytes were suspended in RPMI–
10% fetal bovine serum–1% penicillin/streptomycin–1% L-
glutamine–0.1% BME to a concentration of 20 £ 106 cells/ml.
Single cell splenocytes/lymphocytes suspensions were transferred
at 1.0 to 2.0 £ 106 cells/well to round bottom plates. Individual
and pooled peptides were evaluated at 10 mg/ml. Controls con-
sisted of wells incubated with medium alone or PMA/
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Ionomycin. Plates were incubated for 20 hours at 37C, 5%
CO2 prior to addition of Brefeldin A and returned to the incuba-
tor for another 4 hours. At the end of the incubation period cells
were harvested and stained for flow cytometry.
At 24 hours, cells were spun down, and washed by addition of
FACS staining buffer (5% FBS in PBS). Antibodies against CD3,
CD4, CD8, CD45, were added and cells were incubated on ice
in the dark for 30 minutes. After washing with FACS staining
buffer, cells were fixed and permeabilized for 20 minutes on ice.
After washing with perm/wash buffer, cells were stained for inter-
feron-g, IL-4, granzyme B (Ovalbumin and Flu), interferon-g,
granzyme B, IL-4, and IL-17a (Lassa), for 30 minutes on ice.
Cells were washed with perm/wash buffer and rinsed with FACS
staining buffer.
Flow cytometry data acquisition was performed on a BD LSR
FortessaTM using FACsDIVA Software v6.2. A total of 100,000
events were collected. Flow data were analyzed on FlowJo version
8.8.7.
Antibody response
A standard ELISA was used to determine antibody responses
against MtbHSP70, Flu and Lassa Fever virus specific peptides as
described below:
Anti-MtbHSP70
Wells of a 96-wells plate were coated with 100 ml of
MtbHSP70 (2.5 mg/ml) in PBS overnight at 4C. Unbound
MtbHSP70 was removed with 2 PBS washes. Wells were blocked
at room temperature for 2 hours with 2% BSA, 2% sucrose, and
1% normal goat serum in PBS. After removal of block solution,
100 ml of sera diluted in block solution were added to each well
and incubated at room temperature for 1 hour. Plates were
washed 4 times (0.05% Tween 20 in PBS) followed by addition
of 100 ml of a 20,000 fold dilution of HRP-conjugated goat
anti-mouse (Pierce) in blocking buffer. After incubation at room
temperature for 1 hour, plates were washed 4 times as before,
and rinsed once with water. 100 ml of TMB (warmed to room
temperature) were added to each well and the plates incubated in
the dark for 20 minutes at room temperature. The reaction as
stopped by addition of 50 ml of 2N H2SO4. The optical density
at 450 nm minus background at 650 nm was obtained using an
EMAX plate reader from Molecular Device.
Anti-Flu peptides
For the anti-Flu peptides ELISA, streptavidin plates
(Pierce) were coated with 100 ml of a mixture of peptides 1
to 4 from (Table 2B; 10 mg/ml) or of peptides 5 and 6
(Table 2B; 10 mg/ml) diluted in PBS and incubated at 4C
overnight. Unbound peptides were removed with 2 washes
with PBS and then blocked with 1% milk (KPL) in PBS for
2 hours at room temperature. After removing the block solu-
tion, 100 ml of serially diluted sera in 1% Milk diluted in
PBS were added to each well and plates incubated for 1 hour
at room temperature. Plates were washed 3 times (0.05%
Tween 20 in PBS) followed by addition of 100 ml of HRP-
conjugated goat anti-mouse diluted 10,000 fold in 1% milk
and incubated for 1 hours at room temperature. Plates were
then washed 3 times (0.05% Tween 20 in PBS) followed by
a water rinse. 100 ml of TMB (warmed to room temperature)
were added to each well and plates incubated in the dark for
20 minutes at room temperature. The reaction was stopped
by addition of 50 ml of 2N H2SO4. The optical density at
450 nm minus background at 650 nm was obtained using an
EMAX plate reader from Molecular Device.
Anti-Lassa peptides
For the anti-Lassa peptides ELISA, streptavidin plates
(Pierce) were coated with 100 ml of peptides S1 to S6 respec-
tively (Fig. 4B) diluted to 10 mg/ml in PBS and incubated at
4C overnight. Unbound peptides were removed with 2 PBS
washes and then blocked with 1% milk (KPL) in PBS for
2 hours at room temperature. After removing the block solu-
tion, 100 ml of serially diluted sera in 1% Milk diluted in PBS
were added to each well and plates incubated for 1 hour at
room temperature. Plates were washed 3 times (0.05% Tween
20 in PBS) followed by addition of 100 ml of HRP-conjugated
goat anti-mouse diluted 10,000 fold in 1% milk and incubated
for 1 hour at room temperature. Plates were then washed
3 times (0.05% Tween 20 in PBS) followed by a water rinse.
100 ml of TMB (warmed to room temperature) were added to
each well and the plates incubated in the dark for 20 minutes at
room temperature. The reaction was stopped by addition of
50 ml of 2N H2SO4. The optical density at 450 nm minus
background at 650 nm was obtained using an EMAX plate
reader from Molecular Device.
Endpoint titers
Endpoint titers were determined as described by Frey et al.76
Briefly, 95% confidence interval cutoff curves were obtained
from dilutions of non-immune sera. Endpoint titers were deter-
mined by identifying serum dilutions yielding an optical density
lower than the cutoff point. Sample for which all serum dilutions
yielded optical densities below the 95% confidence interval cutoff
curves were recorded as having no titer against the designated
target.
Statistics
Statistical analyses, Kruskal-Wallis and Dunn’s multiple com-
parisons test, were performed using GraphPad Prism6.
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